CNC
NBIX icon

Canandaigua National Corp’s Neurocrine Biosciences NBIX Stock Holding History

Canandaigua National Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$207K Sell
1,735
-157
-8% -$18.4K 0.04% 237
2022
Q3 		$201K Buy
+1,892
New +$192K 0.04% 236
2020
Q4 		– Sell
-2,098
Closed -$202K – 273
2020
Q3 		$202K Buy
+2,098
New +$243K 0.04% 241

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Canandaigua National Corp's NBIX Position: Q4 2022 in Review

Canandaigua National Corp reduced its Neurocrine Biosciences (NBIX) stake by 8.3% in Q4 2022, selling an estimated $18.4K and leaving 1,735 shares worth $207K. The position accounts for 0.04% of the portfolio, ranked #237.

Canandaigua National Corp first reported a position in NBIX in Q3 2020 and has held it in 3 quarters since. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Canandaigua National Corp held 1,735 shares of Neurocrine Biosciences worth $207K as of Q4 2022.
  • Canandaigua National Corp sold 157 Neurocrine Biosciences shares in Q4 2022, an estimated $18.4K.
  • Neurocrine Biosciences made up 0.04% of Canandaigua National Corp's portfolio in Q4 2022, its #237 holding.
  • Canandaigua National Corp first reported a position in Neurocrine Biosciences in Q3 2020 and has held it in 3 quarters since.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Canandaigua National Corp's 13F filing for Q4 2022, filed 25 Jan 2023.